Meliora Therapeutics Announces Appointment of Biopharma Luminaries to Board of Directors
2024年7月17日 - 8:00PM
ビジネスワイヤ(英語)
Meliora Therapeutics (“Meliora”), a machine learning
therapeutics company developing novel and transformative cancer
drugs, today announced the appointment of Dieter Weinand, former
Chairman and CEO of Bayer Pharmaceuticals, as Meliora’s Chairman of
the Board, and the appointment of Jean-Jacques Bienaimé, former
Chairman and CEO of BioMarin, to Meliora’s Board of Directors as
Independent Director.
“We are thrilled to have Dieter Weinand and Jean-Jacques
Bienaimé join Meliora’s Board of Directors,” stated David Li,
Meliora co-founder and Chief Executive Officer. “Their expertise
and leadership in drug development will be incredible assets to our
company. I look forward to working closely with both to further
Meliora’s vision of being the world’s leading machine learning
oncology therapeutics company.”
Dieter Weinand is an experienced business leader with over 30
years of experience in the pharmaceutical industry and the former
CEO and Chairman of the Board of Bayer Pharmaceuticals. During a
career stretching back over 30 years, he has held various
responsibilities in general management, commercial, operational and
strategic leadership roles, leading business operations in the
Asia-Pacific region, Europe, the Middle East, Africa, Latin America
and the United States, for companies including Bayer, Pfizer,
Bristol-Myers Squibb, and Sanofi.
He has also led the development, launch, and commercialization
of products in various therapeutic areas, including cardiovascular
diseases, oncology, dermatology, immunology, and respiratory and
inflammatory diseases. He is currently Chairman of the Board of
Replimune (REPL), Umoja, and Inspirna, and Executive Chairman of
the Board of Mnemo Therapeutics. He earned an M.S. in pharmacology
and toxicology from Long Island University, New York, and a B.A. in
biology from Concordia College, New York.
“I am very pleased to become Chairman of the Board for Meliora,
a company which has the potential to make a significant clinical
difference in cancer patients’ lives using its novel machine
learning powered approach. I look forward to working together with
David and the Meliora team to advance the company through its next
stages of growth and to achieve its strategic business and pipeline
objectives,” Mr. Weinand commented.
Mr. Jean-Jacques Bienaimé has over three decades of experience
in the biotechnology and pharmaceutical industries, most recently
serving as Chairman and Chief Executive Officer of BioMarin
Pharmaceuticals. He joined BioMarin in May 2005, when the company
had a single marketed product and approximately $26 million in
annual revenues. Under Mr. Bienaimé's leadership, BioMarin grew
significantly, from about 300 US-only employees to more than 3,400
people in almost 80 countries around the world and over $2.4
billion in sales in 2023. Biomarin received 8 drug approvals by the
FDA during this time period.
Before joining BioMarin, Mr. Bienaimé spent years in similar
executive roles at other pharmaceutical and biotech companies and
currently serves on the board of directors for Incyte, Immunome,
Owkin, and Keros. Mr. Bienaimé studied economics at the École de
Commerce de Paris and received an M.B.A from the University of
Pennsylvania.
“I am excited to join the Meliora Board of Directors as they
endeavor to bring transformative oncology therapeutics to the
patients most in need through their ML-powered approach,” commented
Mr. Bienaimé. “In my career, focusing on patients while leveraging
the latest technology has been critical to success, and Meliora is
highly aligned in this approach. I look forward to enhancing
Meliora’s ability to execute on its compelling vision.”
About Meliora Therapeutics
Meliora Therapeutics is discovering and developing small
molecule oncology therapies for high value cancer targets with its
proprietary machine learning powered platform, AnchorOmics. Pairing
the first multimodal, mechanism-of-action machine learning
algorithm and a world-class team of scientists and engineers,
Meliora is pioneering a novel approach to create life-changing
therapies for cancer patients. San Francisco and Cambridge-based
Meliora Therapeutics has raised $11 million to date and is led by
leaders from the fields of AI, biotechnology, and drug discovery.
For more information, please visit: www.melioratx.com
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240716836603/en/
David Li, Chief Executive Officer Meliora Therapeutics Phone:
630-991-6684 Email: david@melioratherapeutics.com